AR115455A1 - Derivado de piridotriazina policíclica - Google Patents
Derivado de piridotriazina policíclicaInfo
- Publication number
- AR115455A1 AR115455A1 ARP190101467A ARP190101467A AR115455A1 AR 115455 A1 AR115455 A1 AR 115455A1 AR P190101467 A ARP190101467 A AR P190101467A AR P190101467 A ARP190101467 A AR P190101467A AR 115455 A1 AR115455 A1 AR 115455A1
- Authority
- AR
- Argentina
- Prior art keywords
- taken together
- alkyl
- membered non
- ring
- independently
- Prior art date
Links
- HHQDNOXLJMIISM-UHFFFAOYSA-N pyrido[3,2-d]triazine Chemical class C1=NN=NC2=CC=CN=C21 HHQDNOXLJMIISM-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical class 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado por la formula (1) o su sal aceptable desde el punto de vista farmacéutico, en donde el anillo A de fórmula (2) es el anillo de fórmula (3) ó (4); X¹ es CR⁹ᵃR⁹ᵇ u O; R⁵ᵃ, R⁵ᵇ, R⁶ᵃ, R⁶ᵇ, R⁷ᵃ y R⁷ᵇ son, cada uno independientemente, un átomo de hidrógeno, alquilo, alquiloxi o alquiloxialquilo; R⁵ᵃ y R⁶ᵃ, o R⁶ᵃ y R⁷ᵃ se pueden tomar junto con los átomos adyacentes para formar un carbociclo aromático opcionalmente sustituido con halógeno, un carbociclo no aromático de 3 a 6 miembros opcionalmente sustituido con halógeno o un heterociclo no aromático de 4 a 6 miembros opcionalmente sustituido con halógeno (siempre que en caso de formar un carbociclo aromático, R⁵ᵇ y R⁶ᵇ, o R⁶ᵇ y R⁷ᵇ se puedan tomar juntos para formar un enlace); R⁵ᵇ y R⁶ᵇ se pueden tomar juntos para formar un enlace; R⁸ᵃ, R⁸ᵇ, R⁹ᵃ, R⁹ᵇ, R¹⁰ᵃ, R¹⁰ᵇ, R¹¹ᵃ y R¹¹ᵇ son, cada uno independientemente, un átomo de hidrógeno, alquilo, alquiloxi o alquiloxialquilo; R⁸ᵃ y R¹⁰ᵃ se pueden tomar juntos para formar un puente C₁₋₃; R¹⁰ᵃ y R¹¹ᵃ se pueden tomar en conjunto con los átomos adyacentes para formar un carbociclo no aromático de 5 miembros; R⁹ᵃ y R⁹ᵇ se pueden tomar junto con el átomo adyacente para formar un carbociclo no aromático de 4 miembros o un heterociclo no aromático de 5 miembros; R⁸ᵃ y R⁹ᵃ se pueden tomar juntos para formar un enlace; el anillo B es un anillo de benceno o un anillo de piridina; Q es -NHC(O)- o un heterociclo aromático de 5 miembros; R¹ es, cada uno independientemente, halógeno, alquilo, haloalquilo, alquiloxi, ciano o haloalquiloxi, R²ᵃ y R²ᵇ son, cada uno independientemente, un átomo de hidrógeno, alquilo o haloalquilo; R³ es alquilo o haloalquilo; R⁴ es un átomo de hidrógeno o alquilo; y n es un entero de 1 a 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018104156 | 2018-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR115455A1 true AR115455A1 (es) | 2021-01-20 |
Family
ID=68698918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101467A AR115455A1 (es) | 2018-05-31 | 2019-05-30 | Derivado de piridotriazina policíclica |
Country Status (22)
Country | Link |
---|---|
US (2) | US11649236B2 (es) |
EP (2) | EP4257137A3 (es) |
JP (2) | JP7328962B2 (es) |
KR (1) | KR20210015922A (es) |
CN (2) | CN117327072A (es) |
AR (1) | AR115455A1 (es) |
AU (2) | AU2019277548B2 (es) |
BR (1) | BR112020024077A2 (es) |
CA (1) | CA3102063A1 (es) |
CL (1) | CL2020003002A1 (es) |
CO (1) | CO2020014294A2 (es) |
CR (2) | CR20200644A (es) |
DO (1) | DOP2020000221A (es) |
EA (1) | EA202092921A1 (es) |
IL (1) | IL279051A (es) |
MA (1) | MA52795A (es) |
MX (2) | MX2020012176A (es) |
PE (1) | PE20210477A1 (es) |
PH (1) | PH12020552000A1 (es) |
SG (1) | SG11202011382PA (es) |
WO (1) | WO2019230858A1 (es) |
ZA (1) | ZA202007567B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021011394A (es) | 2019-03-22 | 2021-10-13 | Gilead Sciences Inc | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico. |
WO2021107065A1 (ja) * | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | 多環性ピリドピラジン誘導体 |
TW202133858A (zh) * | 2019-11-28 | 2021-09-16 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥 |
JP7453399B2 (ja) | 2020-02-24 | 2024-03-19 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv感染症を治療するための四環式化合物及びその使用 |
US20230212187A1 (en) * | 2020-05-21 | 2023-07-06 | Cisen Pharmaceutical Co., Ltd | Fused ring derivatives and use thereof in pharmacy |
WO2022026285A1 (en) * | 2020-07-27 | 2022-02-03 | Merck Sharp & Dohme Corp. | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza |
WO2022159387A1 (en) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
WO2023006087A1 (zh) * | 2021-07-30 | 2023-02-02 | 南京明德新药研发有限公司 | 大环吡啶酮类化合物及其应用 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2024061257A1 (zh) * | 2022-09-20 | 2024-03-28 | 吉斯凯(苏州)制药有限公司 | 多环氮杂环酮类化合物及其应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003267098B2 (en) | 2002-09-11 | 2008-11-20 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors |
US7414045B2 (en) | 2002-12-27 | 2008-08-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
EP1852434B1 (en) | 2005-02-21 | 2011-07-13 | Shionogi Co., Ltd. | Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity |
EP3372281B1 (en) | 2005-04-28 | 2021-07-07 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
US8188271B2 (en) | 2005-10-27 | 2012-05-29 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
SG183484A1 (en) | 2010-02-26 | 2012-09-27 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
US9216995B2 (en) | 2010-04-12 | 2015-12-22 | Shionogi & Co., Ltd. | Pyridone derivative having integrase inhibitory activity |
WO2013054862A1 (ja) | 2011-10-12 | 2013-04-18 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
WO2014099586A1 (en) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
MD4841B1 (ro) | 2012-12-21 | 2023-01-31 | Gilead Sciences, Inc. | Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică |
RU2015131006A (ru) | 2012-12-27 | 2017-01-30 | Джапан Тобакко Инк. | ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ) |
ME02977B (me) | 2013-05-17 | 2018-10-20 | Merck Sharp & Dohme | Fuzionisana triciklicna heterociklicna jedinjenja као inhibiтori hiv integraze |
US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
EP3252058B1 (en) | 2013-07-12 | 2021-01-20 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
EA030695B1 (ru) | 2013-09-27 | 2018-09-28 | Мерк Шарп И Доум Корп. | Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич |
WO2015089847A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
WO2015199167A1 (ja) | 2014-06-25 | 2015-12-30 | 日本たばこ産業株式会社 | 置換されたスピロピリド[1,2-a]ピラジン誘導体の製造方法および中間体 |
WO2016027879A1 (ja) | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
US10150780B2 (en) | 2014-12-09 | 2018-12-11 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as HIV integrase inhibitors |
WO2016090545A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
EP3285582B1 (en) | 2015-03-26 | 2020-11-11 | Merck Sharp & Dohme Corp. | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors |
SG11201707905WA (en) | 2015-04-02 | 2017-10-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
US10624912B2 (en) | 2015-11-17 | 2020-04-21 | Merck Sharp & Dohme Corp. | Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors |
US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
WO2019160783A1 (en) | 2018-02-15 | 2019-08-22 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
WO2019209667A1 (en) | 2018-04-27 | 2019-10-31 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
MA52802A (fr) | 2018-05-31 | 2021-04-14 | Shionogi & Co | Dérivé de pyridone polycyclique |
EP3801543A4 (en) | 2018-06-05 | 2022-03-02 | Merck Sharp & Dohme Corp. | HETEROCYCLIC TRICYCLIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS |
CN108957755B (zh) | 2018-07-27 | 2021-04-30 | 京东方科技集团股份有限公司 | 一种显示组件及其控制方法、平视显示器及汽车 |
MX2021011394A (es) | 2019-03-22 | 2021-10-13 | Gilead Sciences Inc | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico. |
-
2019
- 2019-05-30 EP EP23192706.2A patent/EP4257137A3/en active Pending
- 2019-05-30 CR CR20200644A patent/CR20200644A/es unknown
- 2019-05-30 EA EA202092921A patent/EA202092921A1/ru unknown
- 2019-05-30 MA MA052795A patent/MA52795A/fr unknown
- 2019-05-30 US US17/058,251 patent/US11649236B2/en active Active
- 2019-05-30 CR CR20230571A patent/CR20230571A/es unknown
- 2019-05-30 WO PCT/JP2019/021446 patent/WO2019230858A1/ja active Application Filing
- 2019-05-30 JP JP2020522577A patent/JP7328962B2/ja active Active
- 2019-05-30 EP EP19810498.6A patent/EP3805220A4/en active Pending
- 2019-05-30 PE PE2020001863A patent/PE20210477A1/es unknown
- 2019-05-30 CA CA3102063A patent/CA3102063A1/en active Pending
- 2019-05-30 AU AU2019277548A patent/AU2019277548B2/en active Active
- 2019-05-30 CN CN202311258763.1A patent/CN117327072A/zh active Pending
- 2019-05-30 BR BR112020024077-0A patent/BR112020024077A2/pt unknown
- 2019-05-30 MX MX2020012176A patent/MX2020012176A/es unknown
- 2019-05-30 KR KR1020207037580A patent/KR20210015922A/ko not_active Application Discontinuation
- 2019-05-30 SG SG11202011382PA patent/SG11202011382PA/en unknown
- 2019-05-30 AR ARP190101467A patent/AR115455A1/es unknown
- 2019-05-30 CN CN201980050399.5A patent/CN112513042B/zh active Active
-
2020
- 2020-11-13 MX MX2023010377A patent/MX2023010377A/es unknown
- 2020-11-18 CO CONC2020/0014294A patent/CO2020014294A2/es unknown
- 2020-11-18 CL CL2020003002A patent/CL2020003002A1/es unknown
- 2020-11-20 PH PH12020552000A patent/PH12020552000A1/en unknown
- 2020-11-27 DO DO2020000221A patent/DOP2020000221A/es unknown
- 2020-11-29 IL IL279051A patent/IL279051A/en unknown
- 2020-12-04 ZA ZA2020/07567A patent/ZA202007567B/en unknown
-
2023
- 2023-03-22 US US18/124,827 patent/US20230227454A1/en active Pending
- 2023-08-03 JP JP2023127333A patent/JP2023145723A/ja active Pending
-
2024
- 2024-02-08 AU AU2024200783A patent/AU2024200783A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR115455A1 (es) | Derivado de piridotriazina policíclica | |
CO2017010384A2 (es) | Derivados de piridona policíclica sustituida y profármaco de los mismos | |
AR123048A2 (es) | Moduladores de p2x7 | |
AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR111689A1 (es) | Tienopiridinas y benzotiofenos útiles como inhibidores de irak4 | |
AR108109A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
AR091112A1 (es) | Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7 | |
AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR102799A1 (es) | Profármacos de agonistas fenólicos de trpv1 | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR117978A1 (es) | Inhibidores de 15-pgdh | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
AR092347A1 (es) | Derivados de azaindol | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
ES2682398T3 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
AR104121A1 (es) | DERIVADOS DE ANILLOS FUSIONADOS DE 9 MIEMBROS CON ACCIÓN SOBRE ACETIL CoA CARBOXILASA | |
AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
PE20240928A1 (es) | Derivados de triazina y su uso en el tratamiento del cancer | |
AR116400A1 (es) | Compuesto de imidazopiridinona |